Patients with metastatic, castration-resistant prostate cancer saw significant benefits from the combination of Xofigo and Xtandi. For patients with metastatic, castration-resistant prostate cancer ...
The FDA has granted a priority review for the evaluation of Xtandi as a treatment for patients with non-metastatic castration-sensitive prostate cancer. The Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results